Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue (2018 - 2022)

Summit Therapeutics (SMMT) has disclosed Current Deferred Revenue for 4 consecutive years, with $3.2 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Current Deferred Revenue fell 56.95% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Jun 2022, down 56.95%, and an annual FY2021 reading of $7.9 million, down 5.15% over the prior year.
  • Current Deferred Revenue was $3.2 million for Q2 2022 at Summit Therapeutics, down from $5.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $8.4 million in Q4 2020 and bottomed at $2.6 million in Q4 2019.
  • Average Current Deferred Revenue over 4 years is $6.3 million, with a median of $7.4 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue skyrocketed 220.08% in 2020, then plummeted 56.95% in 2022.
  • Year by year, Current Deferred Revenue stood at $2.6 million in 2019, then surged by 220.08% to $8.4 million in 2020, then fell by 5.15% to $7.9 million in 2021, then tumbled by 59.3% to $3.2 million in 2022.
  • Business Quant data shows Current Deferred Revenue for SMMT at $3.2 million in Q2 2022, $5.1 million in Q1 2022, and $7.9 million in Q4 2021.